Educación
Facultad de Medicina: Universidad Ben Gurion
Especialización
Experiencia Reconocido
Medicina Interna y Hematología
Educación adicional
NHLBI/NIH, Bethesda, EE. UU.
Experiencia clínica
Experiencia academica
Publicaciones profesionales
Más de 80 publicaciones profesionales
Membresía de la unión
Zonas de especial interés y actividades
Tratamiento e investigación en LLC
Mostrar másEducación
Facultad de Medicina: Universidad Ben Gurion
Especialización
Experiencia Reconocido
Medicina Interna y Hematología
Educación adicional
NHLBI/NIH, Bethesda, EE. UU.
Experiencia clínica
Experiencia academica
Publicaciones profesionales
Más de 80 publicaciones profesionales
Membresía de la unión
Zonas de especial interés y actividades
Tratamiento e investigación en LLC
Undergraduate and Doctoral Education:
* 1992-1999 Ondokuz Mayıs University Faculty of Medicine
* 2002-2007 Inonu University, Faculty of Medicine, Child Health and Diseases,
Pediatrics Residency
* 2015-2018 Inonu University, Faculty of Medicine, Pediatrics, Pediatric
Hematology and Oncology Subspecialization
*2017-Ankara University, Pediatrics, Oncology minor residency (8 months)
Mostrar másUndergraduate and Doctoral Education:
* 1992-1999 Ondokuz Mayıs University Faculty of Medicine
* 2002-2007 Inonu University, Faculty of Medicine, Child Health and Diseases,
Pediatrics Residency
* 2015-2018 Inonu University, Faculty of Medicine, Pediatrics, Pediatric
Hematology and Oncology Subspecialization
*2017-Ankara University, Pediatrics, Oncology minor residency (8 months)
El Dr. Dror Levin es pediatra principal y director de los departamentos de tratamiento de trastornos sanguíneos y cáncer de huesos (sarcoma) en el Hospital Infantil "Dana" y el Centro Médico "Sourasky", respectivamente. Es especialista en medicina pediátrica, hematología y oncología, con experiencia adicional estudiando en el extranjero en el Instituto Ortopédico Rizzoli en Italia.
Mostrar másEl Dr. Dror Levin es pediatra principal y director de los departamentos de tratamiento de trastornos sanguíneos y cáncer de huesos (sarcoma) en el Hospital Infantil "Dana" y el Centro Médico "Sourasky", respectivamente. Es especialista en medicina pediátrica, hematología y oncología, con experiencia adicional estudiando en el extranjero en el Instituto Ortopédico Rizzoli en Italia.
El profesor Drach es especialista en oncología con un doctorado de la Universidad de Medicina de Viena. Tiene experiencia en investigación, medicina interna, oncología hematológica, nutrición y estilo de vida en cáncer. Es el Director de la Clínica Privada Josefstadt en Viena y miembro de la Junta Directiva de la Sociedad Austriaca de Hematología y Oncología. Ha publicado más de 120 artículos científicos y dado más de 200 conferencias/presentaciones.
Mostrar másEl profesor Drach es especialista en oncología con un doctorado de la Universidad de Medicina de Viena. Tiene experiencia en investigación, medicina interna, oncología hematológica, nutrición y estilo de vida en cáncer. Es el Director de la Clínica Privada Josefstadt en Viena y miembro de la Junta Directiva de la Sociedad Austriaca de Hematología y Oncología. Ha publicado más de 120 artículos científicos y dado más de 200 conferencias/presentaciones.
Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)
Mostrar másProfessor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)
Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
Mostrar másProf. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.
His medical interests include:
Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)
Acute Leukemia
Chronic Leukemia Treatments
Hodgkin Lymphoma
Non-Hodgkin Lymphoma Treatments
Multiple Myeloma Treatments, MDS
Aplastic Anemia
ITP
TTP Treatments
Hypercoagulability
Hereditary Thrombophilia Treatments
Therapeutic Apheresis
Photopheresis
Geriatric Hematology Diseases.
El Dr. Andrés JM Ferreri es médico oncólogo con más de 300 artículos científicos publicados relacionados con el tratamiento de linfomas. Es Director Adjunto del Departamento de Hematología Oncológica y Director de la Unidad de Linfoma del Instituto Científico San Raffaele, así como Fundador de la Fundación Italiana de Linfoma. Es miembro de varias organizaciones médicas de prestigio y Profesor Contratado de Oncología en la Università Vita-Salute San Raffaele.
Mostrar másEl Dr. Andrés JM Ferreri es médico oncólogo con más de 300 artículos científicos publicados relacionados con el tratamiento de linfomas. Es Director Adjunto del Departamento de Hematología Oncológica y Director de la Unidad de Linfoma del Instituto Científico San Raffaele, así como Fundador de la Fundación Italiana de Linfoma. Es miembro de varias organizaciones médicas de prestigio y Profesor Contratado de Oncología en la Università Vita-Salute San Raffaele.
| Cita con el médico | precio a consultar |
| Trasplante de médula ósea | $172535.57 |
| Terapia de células T con CAR | $129401.68 |
| Quimioterapia |
El Dr. Jaime Pérez de Oteyza es un hematólogo español y jefe del Servicio de Hematología y Oncología Hematológica del Grupo HM Hospitales. Es experto en diagnóstico y tratamiento de patologías hematológicas y trasplante de células madre hematopoyéticas, y ha participado en el primer trasplante de médula ósea en España. Es licenciado en medicina general por la Universidad CEU San Pablo, se ha formado en patología de linfomas en la Universidad de Kiel y tiene una especialidad en hematología y hemoterapia por la Universidad de Alcalá. Ha ganado numerosos premios por su investigación científica y ha publicado más de 40 artículos sobre sus estudios. Es miembro de la Sociedad Española de Hematología y Hemoterapia.
Mostrar másEl Dr. Jaime Pérez de Oteyza es un hematólogo español y jefe del Servicio de Hematología y Oncología Hematológica del Grupo HM Hospitales. Es experto en diagnóstico y tratamiento de patologías hematológicas y trasplante de células madre hematopoyéticas, y ha participado en el primer trasplante de médula ósea en España. Es licenciado en medicina general por la Universidad CEU San Pablo, se ha formado en patología de linfomas en la Universidad de Kiel y tiene una especialidad en hematología y hemoterapia por la Universidad de Alcalá. Ha ganado numerosos premios por su investigación científica y ha publicado más de 40 artículos sobre sus estudios. Es miembro de la Sociedad Española de Hematología y Hemoterapia.
Oncohematólogo, especialista en trasplante de médula ósea
Mostrar másOncohematólogo, especialista en trasplante de médula ósea
El profesor Bosch es un líder de gran reputación en leucemia linfocítica crónica (LLC) y lleva a cabo investigaciones clínicas y básicas sobre la LLC y otros trastornos linfoproliferativos, centrándose en la patogenia molecular de la LLC y nuevos enfoques terapéuticos. Ha publicado más de 100 artículos en revistas de prestigio y es profesor de hematología en el Hospital Universitario Vall d'Hebron de Barcelona.
Mostrar másEl profesor Bosch es un líder de gran reputación en leucemia linfocítica crónica (LLC) y lleva a cabo investigaciones clínicas y básicas sobre la LLC y otros trastornos linfoproliferativos, centrándose en la patogenia molecular de la LLC y nuevos enfoques terapéuticos. Ha publicado más de 100 artículos en revistas de prestigio y es profesor de hematología en el Hospital Universitario Vall d'Hebron de Barcelona.
Hematólogo-oncólogo pediátrico, especialista en trasplante de médula ósea
Mostrar másHematólogo-oncólogo pediátrico, especialista en trasplante de médula ósea